Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole

Aim:  Considering the roles of c‐erB‐2 and p53 oncoproteins in tumor progression, we aimed to evaluate their expression in hydatidiform moles, and the possible predictive value of this immunoexpression in postmolar follow‐up. Methods:  Group I comprised 35 patients with progression to gestational tr...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2006-06, Vol.32 (3), p.265-272
Main Authors: Yazaki-Sun, Sue, Daher, Silvia, De Souza Ishigai, Márcia Marcelino, Alves, Maria Teresa Seixas, Mantovani, Teresa Meire, Mattar, Rosiane
Format: Article
Language:English
Subjects:
Adolescent
Adult
c-erbB-2
Cell Transformation, Neoplastic - genetics
complete hydatidiform mole
Female
Genes, erbB-2
Genes, p53
gestational trophoblast tumor
Humans
Hydatidiform Mole - genetics
Middle Aged
oncogene
p53
Pregnancy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim:  Considering the roles of c‐erB‐2 and p53 oncoproteins in tumor progression, we aimed to evaluate their expression in hydatidiform moles, and the possible predictive value of this immunoexpression in postmolar follow‐up. Methods:  Group I comprised 35 patients with progression to gestational trophoblastic tumor, and group II included 32 patients with progression to spontaneous remission. Immunohistochemical tests were performed by streptavidin‐peroxidase method. c‐erbB‐2 immunoexpression was evaluated according to quantitative and semiquantitative criteria; p53 according to percentage of cells with stained nuclei. Data were analyzed by Student t‐test, Mann–Whitney test, ROC curve and logistic regression analysis. Results:  c‐erbB‐2 and p‐53 expressions were significantly increased in group I. Quantitative and semiquantitative analysis of c‐erb‐2 showed that its expression may be associated with mole hydatidiform progression to gestational trophoblastic tumor. Taking into account cells with complete membranous delineation we proposed a cut‐off value of 10.8%. Similarly, considering the percentage of cells presenting nuclei marked by p53 we suggested a cut‐off value of 40.1% for the prediction of malignant transformation of mole hydatidiform. Conclusions:  c‐erbB‐2 and p53 immunoexpression in hydatidiform mole are usually increased with malignant transformation. In addition to β‐fraction of human chorionic gonadotropin, they could possibly help the establishment of a therapeutic protocol.
ISSN:1341-8076
1447-0756
DOI:10.1111/j.1447-0756.2006.00397.x